Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

HSTO
Histogen Inc
stock NASDAQ

At Close
3/27/2023 3:59:30 PM EDT
1.17USD0.000%(0.00)101,987
1.13Bid   1.42Ask   0.29Spread IEX
Pre-market
3/27/2023 9:23:30 AM EDT
1.21USD+3.419%(+0.04)172
After-hours
3/22/2023 4:02:30 PM EDT
1.23USD+7.895%(+0.09)0
OverviewHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsNews
Dec 22, 2021
04:15PM EST  Histogen S-3 Shows Registration For ~16.88M Share Common Stock Offer Via Selling Shareholders   Benzinga
Dec 21, 2021
06:19PM EST  Histogen Announces Closing of $3.5 Million Private Placement   GlobeNewswire Inc
Dec 16, 2021
08:07AM EST  Histogen Announces $3.5M Private Placement Of $0.425/Share   Benzinga
08:00AM EST  Histogen Announces $3.5 Million Private Placement   GlobeNewswire Inc
Nov 10, 2021
05:59PM EST  Histogen Q3 EPS $(0.09) Beats $(0.11) Estimate, Sales $591.00K Up From $495.00K YoY   Benzinga
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:08AM EST  Histogen Announces Names Steven Mento As Interim President, CEO   Benzinga
Nov 8, 2021
04:05PM EST  Histogen Announces CEO Transition   GlobeNewswire Inc
Nov 2, 2021
10:54AM EDT  Histogen And Amerimmune Announce The Presentation Of Emricasan Data In COVID-19 At The American College Of Allergy, Asthma, And Immunology Conference   Benzinga
08:00AM EDT  Phase 1 Study in Mild COVID-19 Patients Demonstrated a Favorable Safety and Tolerability Profile and Statistically Significant Clinical Symptom and Biomarker Improvements   GlobeNewswire Inc
Oct 27, 2021
08:00AM EDT  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced that Histogens financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Aug 31, 2021
04:05PM EDT  Histogen to Present at the H.C. Wainwright 23rd Annual Global   GlobeNewswire Inc
Aug 30, 2021
06:18AM EDT  HC Wainwright & Co. Initiates Coverage On Histogen with Buy Rating, Announces Price Target of $2.4   Benzinga
Aug 20, 2021
04:09PM EDT  Histogen Says Received Letter From Nasdaq Indicating Co Did Not Meet Minimum Bid Price $1/Share   Benzinga
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 16, 2021
02:58PM EDT  Histogen Shares Additional Emricasan Data From COVID-19 Study   Benzinga
08:03AM EDT  Histogen and Amerimmune Announce Additional Findings From Phase 1 Study Of Emricasan In Mild Symptomatic COVID-19 Patients; Says Emricasan Found To Have Statistically Significant Improvements In Clinically Relevant Hematological And Immune Markers   Benzinga
08:00AM EDT  ImmunologicalData Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression   GlobeNewswire Inc
Aug 11, 2021
04:13PM EDT  Histogen Q2 EPS $(0.10) Beats $(0.17) Estimate, Sales $5.00K Down From $108.00K YoY   Benzinga
04:05PM EDT  Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates   GlobeNewswire Inc
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 28, 2021
04:05PM EDT  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced that Histogens financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.   GlobeNewswire Inc
Jun 30, 2021
08:22AM EDT  Histogen Begins HST 003 Phase 1/2 Trial In Knee To Regenerate Hyaline Cartilage With A Microfracture Procedure   RTTNews
08:01AM EDT  Histogen Reports Initiation Of HST 003 Phase 1/2 Trial For Knee Cartilage Regeneration   Benzinga
08:00AM EDT  Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee   GlobeNewswire Inc
Jun 22, 2021
10:14AM EDT  Histogen Stock Is Trading Higher As Emricasan Shows Complete, Early Resolution of COVID-19 Symptoms Compared To Placebo   Benzinga
08:01AM EDT  Histogen Amerimmune Report Top-Line Study Results From Phase 1 Study Of Emricasan In Mild Symptomatic COVID-19 Patients: Emricansan Found To Be Safe, Well Tolerated With No Serious Adverse Events   Benzinga
08:00AM EDT  Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events   GlobeNewswire Inc
Jun 16, 2021
04:16PM EDT  Intracoastal Capital Reports In 13G Filing A 5.6% Stake In Histogen   Benzinga
Jun 9, 2021
04:01PM EDT  Histogen Announces Closing of $6.5 Million Registered Direct   GlobeNewswire Inc
Jun 8, 2021
02:38PM EDT  Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Aclaris Therapeutics Shares Plunge   Benzinga
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
07:39AM EDT  Histogen Secures $6.5M Via Direct Equity Offering   Benzinga
Jun 7, 2021
04:17PM EDT  Histogen Announces $6.5M Registered Direct Offering Of 5.977M Shares Priced At-the-Market   Benzinga
04:05PM EDT  Histogen Announces $6.5 Million Registered Direct Offering Priced   GlobeNewswire Inc
Jun 4, 2021
10:03AM EDT  Canaccord Genuity Maintains Buy on Histogen, Lowers Price Target to $4   Benzinga
Jun 3, 2021
12:29PM EDT  Histogen Stops HST 001 Development After Trial Failure, Shifts Focus On Programs For Orthopedic Indications   Benzinga
08:03AM EDT  Histogen Provides Update On Development Programs And Pipeline Focus   Benzinga
08:00AM EDT  Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates   GlobeNewswire Inc
May 19, 2021
08:03AM EDT  Histogen Partner Amerimmune Highlights Publication Of Emricasan Data In Journal of the European Academy of Allergy and Clinical Immunology   Benzinga
08:00AM EDT  Histogen and Amerimmune Report Publication on Emricasan in COVID-19   GlobeNewswire Inc
May 13, 2021
04:25PM EDT  Histogen Q1 EPS $(0.14) Beats $(0.15) Estimate, Sales $431.00M Down From $978.00M YoY   Benzinga
04:01PM EDT  Strengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
Apr 28, 2021
04:05PM EDT  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced that Histogens financial results for the second quarter will be released after the close of market on Thursday, May 13, 2021.   GlobeNewswire Inc
Mar 30, 2021
08:00AM EDT  Histogen to Present at the 20th Annual Needham Virtual Healthcare   GlobeNewswire Inc
Mar 25, 2021
04:05PM EDT  Histogen Appoints Rochelle Fuhrmann to Board of Directors   GlobeNewswire Inc
Mar 16, 2021
08:02AM EDT  Histogen And Amerimmune Announce First Patient Dosed In Phase 1 Study Of Emricasan In Symptomatic COVID-19 Patients   Benzinga
08:00AM EDT  Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19 patients to assess safety, tolerability, and preliminary efficacy. SUNY Downstate Medical Center in Brooklyn, New York, has been selected as the single site for the study conduct.   GlobeNewswire Inc
Mar 15, 2021
09:04AM EDT  FDA Clears Histogen's HST-003 Early-Stage Study For Knee Cartilage Regeneration   Benzinga
08:08AM EDT  Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration   Benzinga
08:00AM EDT  Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND   GlobeNewswire Inc
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
04:04PM EST  Histogen Q4 EPS $(0.26) Up From $(0.70) YoY, Sales $500.00K Miss $526.00K Estimate   Benzinga
04:01PM EST  Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises   GlobeNewswire Inc
03:35AM EST  Earnings Scheduled For March 11, 2021   Benzinga
Mar 10, 2021
04:05PM EST  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function has appointed Susan R. Windham-Bannister, Ph.D. to its Board of Directors.   GlobeNewswire Inc
Mar 4, 2021
04:05PM EST  Histogen to Report Fourth Quarter and Year-End 2020 Financial   GlobeNewswire Inc
10:11AM EST  Canaccord Genuity Initiates Coverage On Histogen with Buy Rating, Announces Price Target of $5   Benzinga
Mar 2, 2021
08:00AM EST  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced it will present at theH.C. Wainwright Global Life Sciences Virtual Conference.   GlobeNewswire Inc
Feb 16, 2021
08:13AM EST  Histogen Says HST-001 Found To Be 'Safe And Well Tolerated' With No Serious Adverse Events; Says Planning Underway For Next Clinical Study In U.S.   Benzinga
08:00AM EST  HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events   GlobeNewswire Inc
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 19, 2021
04:06PM EST  Histogen Reports FDA Clinical Hold For Planned Phase 1/2 Trial Of HST-003 For Knee Cartilage Regeneration   Benzinga
04:05PM EST  Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of   GlobeNewswire Inc
Jan 7, 2021
09:48AM EST  DLA Piper Advises Histogen In US$14 Mln Upsized Public Offering   RTTNews
09:47AM EST  DLA Piper advises Histogen in its US$14 million upsized public offering   PR Newswire
Jan 6, 2021
08:00AM EST  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced that it will present at theH.C. Wainwright BIOCONNECT 2021 Virtual Conference.   GlobeNewswire Inc
Jan 5, 2021
04:05PM EST  Histogen Announces Closing of $14.0 Million Upsized Public Offering   GlobeNewswire Inc
Jan 4, 2021
05:27PM EST  Histogen Filing Shows Registration For 11.6M Common Share Offering For Stock, Warrants   Benzinga
Dec 31, 2020
02:30PM EST  Mid-Afternoon Market Update: Dow Rises 60 Points; Red Lion Hotels Shares Climb On Acquisition News   Benzinga
Dec 30, 2020
10:54PM EST  Histogen Prices Public Offering Of 14 Mln Shares Together With Accompanying Warrants To Buy 14 Mln Shares At $1/Shr   RTTNews
10:26PM EST  Histogen Announces Pricing of $14.0 Million Upsized Public Offering   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 17, 2020
08:03AM EST  Histogen Announces Filing an Investigational New Drug Application for HST-003   Benzinga
08:00AM EST  Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021   GlobeNewswire Inc
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:05AM EST  Histogen Announces Preliminary Week 18 HST-001 Study Results For Treatment Of Androgenic Alopecia In Men; Says HST-001 Demonstrated Separation From Placebo At Week 18 Primary Efficacy Endpoint Assessment, No Serious Adverse Events   Benzinga
08:00AM EST  HST-001 Demonstrated Separation from Placebo at Week18 Primary Efficacy Endpoint Assessment   GlobeNewswire Inc
Nov 16, 2020
04:05PM EST  Histogen Announces Closing of $4.5 Million Registered Direct   GlobeNewswire Inc
Nov 12, 2020
08:15AM EST  Histogen Announces $4.5M Registered Direct Offering Priced At-the-Market under Nasdaq Rules   Benzinga
08:00AM EST  Histogen Announces $4.5 Million Registered Direct Offering Priced   GlobeNewswire Inc
Nov 10, 2020
04:39PM EST  Histogen Q3 EPS $(0.27) Up From $(0.51) YoY, Sales $495.00K Miss $526.00K Estimate   Benzinga
04:05PM EST  Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20   GlobeNewswire Inc
Oct 27, 2020
08:10AM EDT  Histogen And Amerimmune Enter Collaborative Development And Commercialization Agreement For Emricasan In The Treatment Of COVID-19   Benzinga
08:00AM EDT  Histogen ReceivesIND Approval from FDA to Initiate a Phase 1 Study of Emricasan in Mild-COVID-19 Patients to Assess Safety and Tolerability   GlobeNewswire Inc
Oct 19, 2020
08:00AM EDT  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced the appointment of Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations.   GlobeNewswire Inc
Oct 5, 2020
08:10AM EDT  Histogen Announces Completion Of Final Dosing Timepoint Milestone In Its 1b/2a Trial For Androgenic Alopecia In Men   Benzinga
08:00AM EDT  Histogen Announces Completion of Final Dosing Timepoint Milestone   GlobeNewswire Inc
Sep 29, 2020
08:05AM EDT  Histogen Announces HST-001 Designated As Drug-Biologic-Device Combination Product; Says 1b/2a Trial For Androgenic Alopecia In Men On Track For Top Line Data Results In Q4 2020; Says HST-003 IND Submission For Regeneration Of Cartilage In Knee Expected Q4   Benzinga
08:00AM EDT  HST-002 Designated as Drug-Biologic-Device Combination Product   GlobeNewswire Inc
Sep 16, 2020
02:59PM EDT  Why Histogen's Stock Is Trading Higher Today   Benzinga
08:09AM EDT  Histogen Announces $2M Grant Award From Department Of Defense For Clinical Advancement Of HST-003 For Cartilage Regeneration In The Knee   Benzinga
08:00AM EDT  Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020   GlobeNewswire Inc
Sep 10, 2020
08:16AM EDT  Histogen Announces Completion Of Dosing Milestone In Its 1b/2a Trial For Androgenic Alopecia In Men   Benzinga
08:00AM EDT  Histogen Announces Completion of Dosing Milestone in its 1b/2a   GlobeNewswire Inc
Sep 1, 2020
04:15PM EDT  Histogen to Present at the HC Wainwright 22nd Annual Global   GlobeNewswire Inc
Aug 17, 2020
04:48PM EDT  Histogen Files Prospectus For $125M Mixed Shelf   Benzinga
Aug 13, 2020
04:22PM EDT  Histogen Q2 EPS $(1.52) Down From $(1.17) YoY, Sales $108.00K May Not Compare To $526.00K Estimate   Benzinga
04:05PM EDT  Completed Enrollment for HST-001 Phase 1a/2b Trial for Androgenic Alopecia in Men with Topline Data Expected 4Q20Filed IDE for HST-002 for Treatment of Moderate to Severe Nasolabial FoldsAppointed Susan A. Knudson as Chief Financial Officer   GlobeNewswire Inc
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Jul 29, 2020
04:15PM EDT  Histogen to Present at the Canaccord Genuity 40th Annual Growth   GlobeNewswire Inc
Jul 20, 2020
04:11PM EDT  Histogen Inc. Announces Common Stock Purchase Agreement For $10M With Lincoln Park Capital Fund, LLC   Benzinga
04:10PM EDT  Histogen Inc. Announces Common Stock Purchase Agreement for up to   GlobeNewswire Inc
Jul 14, 2020
05:22AM EDT  Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia in Men   Benzinga
05:00AM EDT  Histogen Announces Completion of Patient Enrollment for its HST   GlobeNewswire Inc


Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC